| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.73 | 15.3% |
| Total Income | 1.73 | 15.3% |
| Expenditure | 9.32 | 16.4% |
| PBT | — | |
| Net Profit | -4.81 | 16.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.02 | 0.0% |
Lineage Cell Therapeutics Reports Q1 2026 Financial Results
13 May 2026 · 13 May, 1:44 am
Summary
Lineage Cell Therapeutics reported its first quarter 2026 financial results, with revenues increasing by $0.2 million to $1.7 million compared to the same period in 2025. The increase was primarily driven by collaboration revenue recognized under a new research collaboration agreement with WDI. Operating expenses increased by $1.3 million to $9.3 million. The net loss attributable to Lineage for the quarter was $4.8 million, or $0.02 per share. The company's cash, cash equivalents, and marketable securities of $53.4 million as of March 31, 2026, are expected to support planned operations into Q2 2028.
Key Highlights
- 1
Lineage Cell Therapeutics reported total revenues of approximately $1.7 million for the three months ended March 31, 2026, an increase of $0.2 million compared to the same period in 2025.
- 2
The company's cash, cash equivalents, and marketable securities totaled $53.4 million as of March 31, 2026, expected to support planned operations into Q2 2028.
- 3
Research and development expenses for the three months ended March 31, 2026, were $4.2 million, an increase of $1.1 million compared to the same period in 2025.
- 4
The net loss attributable to Lineage for the three months ended March 31, 2026, was $4.8 million, or $0.02 per share (basic) and $0.03 per share (diluted).
- 5
The company launched COR1, a new corneal endothelial cell therapy program, utilizing its AlloSCOPE™ platform.
- 6
Lineage met the first milestone with its AlloSCOPE™ 5D manufacturing initiative, aimed at addressing the challenges of large-scale production of undifferentiated pluripotent stem cells.
- 7
A second chronic SCI patient was treated in the OPC1 DOSED device safety study.
Management Comments
Brian M. Culley
This quarter, we continued to build on our developmental and clinical accomplishments. Most notably, we applied our proprietary cell manufacturing technology platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), to launch COR1, our new, wholly-owned corneal endothelial cell therapy program. COR1 is a preclinical asset which we believe benefits from our existing ophthalmology and manufacturing expertise and represents a natural next application of our platform. We also achieved our first milestone with our AlloSCOPE 5D manufacturing initiative, aimed at addressing the challenges of large scale production of undifferentiated pluripotent stem cells. If successful at a larger scale, the overall goal is to leverage this initiative, together with a differentiation protocol, to address the insufficient supply of islet cells needed to support a potential treatment of Type 1 Diabetes. In parallel, we advanced our DOSED study, successfully administering OPC1 to a second chronic SCI participant using a novel delivery system. We also established a new Scientific Advisory Board with recognized and established cell therapy executive Joachim Fruebis, PhD as its founding member. Dr. Fruebis’ extensive experience across ophthalmology, neurology, diabetes, and other key therapeutic areas will help drive the evolution of our cell therapy platform and help to translate our innovations into clinical and commercial success. We look forward to additional updates on further appointments to our SAB throughout the year. This will be an exciting year for Lineage. Our current cell therapy pipeline features seven separate cell types, two of which are in the clinic, and each of which is in development for a discrete indication addressing a significant unmet need. We remain focused on advancing our innovative pipeline through disciplined internal spending and support from external partners, in line with our long-term strategy of creating a leading portfolio of cell-based transplant programs, all based on our core technology and our AlloSCOPE manufacturing platform.
Informational and educational content only. Not investment advice.